Common vitamin added to brain cancer fight in suspended trial
NCT ID NCT04677049
Summary
This study is testing whether adding a form of niacin (Vitamin B3) to the standard first treatment for a serious brain cancer called glioblastoma is safe and if it helps control the disease. The trial aims to find the best dose of niacin and see if it helps patients live longer without their cancer getting worse. It is for adults recently diagnosed with this specific type of brain tumor, but the study is currently suspended.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tom Baker Cancer Centre/Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
Conditions
Explore the condition pages connected to this study.